Treatment of Advanced Melanoma in 2020 and Beyond
Author:
Funder
National Cancer Institute
Melanoma Research Alliance
Cancer Research Foundation
V Foundation
NIH
Publisher
Elsevier BV
Subject
Cell Biology,Dermatology,Molecular Biology,Biochemistry
Reference95 articles.
1. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma;Andtbacka;J Clin Oncol,2015
2. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma;Andtbacka;J Immunother Cancer,2019
3. Combination treatment with cobimetnib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (PTS) with BRAFV600 wild type (WT) advanced melanoma: primary analysis from the phase 3 IMSPIRE170 trial;Arance;Ann Oncol,2019
4. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma;Ascierto;Nat Med,2019
5. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993;Atkins;J Clin Oncol,1999
Cited by 231 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database;Frontiers in Pharmacology;2024-09-09
2. Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance;Pharmacological Research;2024-09
3. Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway;2024-08-27
4. mRNA vaccines in the treatment of cancer;Oncology in Clinical Practice;2024-08-06
5. Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study;ESMO Open;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3